MaaT Pharma to Host Virtual KOL Event on MaaT013 and MaaT033 Following ASH 2023 Presentations
2023年12月13日 - 2:00AM
ビジネスワイヤ(英語)
- The event will highlight positive efficacy and good safety
results from 111 patients with acute graft-versus-host disease
(aGvHD) treated with MaaT013 in the Early Access Program which have
been presented at the American Society of Hematology (ASH) Annual
Meeting
- Virtual KOL event will be held on Monday, December 18, 2023, at
6.00 pm CET/ 12.00 pm EST
Regulatory News:
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage
biotechnology company and a leader in the development of Microbiome
Ecosystem TherapiesTM (MET) dedicated to enhancing survival of
patients with cancer, announced that it will host a virtual KOL
(Key Opinion Leader) event on data presented during the 2023 ASH
annual meeting including efficacy and safety results for its lead
drug candidate, MaaT013, currently in development for acute
Graft-versus-Host Disease (aGvHD) and details on MaaT033, developed
as an adjuvant therapy to improve patients’ survival following
allogeneic hematopoietic stem cell transplantation (allo-HSCT), on
Monday, December 18, 2023, at 6:00 pm CET (12:00 pm EST).
The event will feature presentations from the Company’s CEO and
co-founder, Hervé Affagard as well as the following KOLs:
- Mohamad Mohty, M.D., Ph.D., Professor of
Hematology at Sorbonne University, and head of the Clinical
Hematology and Cellular Therapy Department at Saint-Antoine
Hospital, Paris, France will comment on the positive data on
MaaT013 presented for the Early Access Program; and
- Florent Malard, M.D., Ph.D., Professor of Hematology at
the Saint-Antoine Hospital and Sorbonne University, Principal
investigator of Phase 2b trial evaluating MaaT033 in patients
receiving allo-HSCT, will provide detailed information on the
ongoing trial.
Virtual KOL Event Details
- Date & time: Monday, December 18, 2023, at 6:00 pm
CET (12:00 pm EST).
- Registration & link to access the event:
https://app.livestorm.co/newcap-1/maat-pharma-presentation?type=detailed
- A replay will be made available on the Company’s website for at
least 90 days.
---
About MaaT Pharma
MaaT Pharma, a clinical stage biotechnology company, has
established a complete approach to restoring patient-microbiome
symbiosis in oncology. Committed to treating cancer and
graft-versus-host disease (GvHD), a serious complication of
allogeneic stem cell transplantation, MaaT Pharma launched, in
March 2022, an open-label, single arm, phase 3 clinical trial in
patients with acute GvHD (aGvHD), following the achievement of its
proof of concept in a phase 2 trial. Its powerful discovery and
analysis platform, gutPrint®, enables the identification of novel
disease targets, evaluation of drug candidates, and identification
of biomarkers for microbiome-related conditions. The company’s
Microbiome Ecosystem Therapies are produced through a standardized
cGMP manufacturing and quality control process to safely deliver
the full diversity of the microbiome, in liquid and oral
formulations. MaaT Pharma benefits from the commitment of
world-leading scientists and established relationships with
regulators to support the integration of the use of microbiome
therapies in clinical practice. MaaT Pharma is listed on Euronext
Paris (ticker: MAAT).
Forward-looking Statements
All statements other than statements of historical fact included
in this press release about future events are subject to (i) change
without notice and (ii) factors beyond the Company’s control. These
statements may include, without limitation, any statements preceded
by, followed by, or including words such as “target,” “believe,”
“expect,” “aim”, “intend,” “may,” “anticipate,” “estimate,” “plan,”
“project,” “will,” “can have,” “likely,” “should,” “would,” “could”
and other words and terms of similar meaning or the negative
thereof. Forward-looking statements are subject to inherent risks
and uncertainties beyond the Company’s control that could cause the
Company’s actual results or performance to be materially different
from the expected results or performance expressed or implied by
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231212457321/en/
MaaT Pharma – Investor Relations Guilhaume DEBROAS, Ph.D.
Head of Investor Relations +33 6 16 48 92 50 invest@maat-pharma.com
MaaT Pharma – Media Relations Pauline RICHAUD Senior PR
& Corporate Communications Manager +33 6 14 06 45 92
media@maat-pharma.com Trophic Communications Jacob VERGHESE
or Priscillia PERRIN +49 151 7441 6179 maat@trophic.eu
Maat Pharma (EU:MAAT)
過去 株価チャート
から 3 2024 まで 4 2024
Maat Pharma (EU:MAAT)
過去 株価チャート
から 4 2023 まで 4 2024